Terms: = Brain cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
679 results:
1. Clinical Management of Patients with Non-Small Cell Lung cancer, brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
2. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
3. Proteomics-based Model for Predicting the Risk of brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the egfr Mutation.
Deng Q; Wang F; Song L; Chen L; Huang Y; Guo Z; Yang H
Int J Med Sci; 2024; 21(4):765-774. PubMed ID: 38464823
[No Abstract] [Full Text] [Related]
4. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
Zechel C; Loy M; Wegner C; Dahlke E; Soetje B; Baehr L; Leppert J; Ostermaier JJ; Lueg T; Nielsen J; Elßner J; Willeke V; Marzahl S; Tronnier V; Madany Mamlouk A
PLoS One; 2024; 19(2):e0291368. PubMed ID: 38306361
[TBL] [Abstract] [Full Text] [Related]
5. Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
Liang Q; Jing H; Shao Y; Wang Y; Zhang H
Clin Neuroradiol; 2024 Mar; 34(1):33-43. PubMed ID: 38277059
[TBL] [Abstract] [Full Text] [Related]
6. Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma.
Shaikh MAJ; Altamimi ASA; Afzal M; Gupta G; Singla N; Gilhotra R; Almalki WH; Kazmi I; Alzarea SI; Prasher P; Singh SK; Dua K
Pathol Res Pract; 2024 Feb; 254():155121. PubMed ID: 38262269
[TBL] [Abstract] [Full Text] [Related]
7. nSEA: n-Node Subnetwork Enumeration Algorithm Identifies Lower Grade Glioma Subtypes with Altered Subnetworks and Distinct Prognostics.
Zhang Z; Wang C; Zhao Z; Yi Z; Durmaz A; Yu JS; Bebek G
Pac Symp Biocomput; 2024; 29():521-533. PubMed ID: 38160304
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Spiekman IAC; Geurts BS; Zeverijn LJ; de Wit GF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Kusters B; Beerepoot LV; de Vos FYFL; de Groot DA; de Groot JWB; Hoeben A; Buter J; Gelderblom HAJ; Voest EE; Verheul HMW
Oncologist; 2024 May; 29(5):431-440. PubMed ID: 38109296
[TBL] [Abstract] [Full Text] [Related]
9. RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Chen Y; Mu Y; Guan Q; Li C; Zhang Y; Xu Y; Zhou C; Guo Y; Ma Y; Zhao M; Ji G; Liu P; Sun D; Sun H; Wu N; Jin Y
Cell Death Dis; 2023 Nov; 14(11):757. PubMed ID: 37985768
[TBL] [Abstract] [Full Text] [Related]
10. Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience.
Molica C; Gili A; Nardelli C; Pierini T; Arniani S; Beacci D; Mavridou E; Mandarano M; Corinaldesi R; Metro G; Gorello P; Giovenali P; Cenci N; Castrioto C; Lupattelli M; Roila F; Mecucci C; La Starza R
Sci Rep; 2023 Nov; 13(1):20101. PubMed ID: 37973912
[TBL] [Abstract] [Full Text] [Related]
11. Stroke as initial manifestation of non-small cell lung cancer with Trousseau syndrome.
Hong W; Zhang T; Shan C; Li H; Lin T; Liu D; Zhen J; Li J; Lai M; Zhou Z; Zhou C; Zhou M; Wang M; Cai L; Wen L
BMC Cancer; 2023 Nov; 23(1):1096. PubMed ID: 37950224
[TBL] [Abstract] [Full Text] [Related]
12. IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy.
Luo Q; Zhuang J; Zheng D; Miao C; Luo H; Peng J; Zheng C; Qin C; Lan C; Chen M; Xia Y; Huang D; Chen Z
Front Immunol; 2023; 14():1282734. PubMed ID: 37928523
[TBL] [Abstract] [Full Text] [Related]
13. Comparative Analysis of the Prognostic Significance of IDH,TERT, egfr and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
[TBL] [Abstract] [Full Text] [Related]
14. A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to egfr-TKIs.
Cai R; Liu Y; Yu M; Sha H; Guo M; Chen Y; Ye J; Zhou G; Fang Y; Shen B
Cancer Immunol Immunother; 2023 Dec; 72(12):4355-4365. PubMed ID: 37907645
[TBL] [Abstract] [Full Text] [Related]
15. Exploring the association of glioma tumor residuals from incongruent [
Li X; Cheng Y; Han X; Cui B; Li J; Yang H; Xu G; Lin Q; Xiao X; Tang J; Lu J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):779-796. PubMed ID: 37864593
[TBL] [Abstract] [Full Text] [Related]
16. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
[TBL] [Abstract] [Full Text] [Related]
17. Epigenomic perturbation of novel egfr enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Vincent CA; Nissen I; Dakhel S; Hörnblad A; Remeseiro S
BMC Cancer; 2023 Oct; 23(1):945. PubMed ID: 37803333
[TBL] [Abstract] [Full Text] [Related]
18. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract] [Full Text] [Related]
19. Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India.
Thomas R; Balaram G; Varayathu H; Ghorpade SN; Kowsik PV; Dharman B; Thomas BE; Ramaswamy V; Nanjaiah T; Patil S; Naik R; Basavalinga AK; Ghosh M
J Cancer Res Ther; 2023; 19(5):1398-1406. PubMed ID: 37787315
[TBL] [Abstract] [Full Text] [Related]
20. Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas.
Furuta T; Negoto T; Miyoshi H; Moritsubo M; Nakamura H; Morioka M; Akiba J; Ohshima K; Sugita Y
J Neurooncol; 2023 Sep; 164(3):633-641. PubMed ID: 37710025
[TBL] [Abstract] [Full Text] [Related]
[Next]
